Plain-English translation of NCT04616560 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called to treat three rare childhood cancers: Wilms tumor (a kidney cancer), osteosarcoma (a bone cancer), and desmoplastic small round cell tumor. The study is designed in two parts: first, researchers will find the right dose of this medication that is safe for younger children (ages 2-12), and then they will test whether the treatment works against these cancers in older children and young adults. The medication is given through an IV infusion every three weeks.
These three cancers are rare in children, and when they come back after initial treatment or stop responding to standard therapies, treatment options become very limited. This trial exists to find out whether this new medication can help children whose cancers have returned or become resistant to earlier treatments.
You likely qualify if…
You likely don't qualify if…
You would receive the medication through an IV infusion (a needle in your vein) over 30 to 90 minutes on the first day of each 3-week cycle. Treatment continues for up to 35 cycles (about 2 years) unless your cancer gets worse or side effects become too severe. Throughout the study, you will have regular visits for blood tests, imaging scans (CT or MRI), heart function tests, and checkups to monitor how you're responding and to check for any side effects. Your doctors will also collect information about how the medication moves through your body.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States